ArticleCancer cell2018
The Integrated Genomic Landscape of Thymic Epithelial Tumors.
2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 240 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 2 pooled it
26.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas
NCT07343453 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
Who cites it
240 citing papers in PubMed, 2 syntheses or guidelines pooled it, 375 citations in OpenAlex.
- Genomic landscape and subgroup stratification of thymic epithelial tumors: a systematic meta-analysis of next-generation sequencing data.Frontiers in oncology · 2026Pooled it
- Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis.Radiology and oncology · 2023Pooled it
- Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.Journal for immunotherapy of cancer · 2026Trial
- Molecular predictors of response to pembrolizumab in thymic carcinoma.Cell reports. Medicine · 2021Trial
- Thymic epithelial tumors: what's next?Cancer metastasis reviews · 2026Review
- Immune checkpoint inhibitors in thymic epithelial tumors: current evidence, immune-related toxicity, and perioperative considerations-a narrative review.Journal of thoracic disease · 2026Review
- Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.JTO clinical and research reports · 2026Article
- Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.International journal of molecular sciences · 2026Review
- Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review.Cancers · 2026Review
- A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymus.Nature communications · 2026Article
- Distinct Associations ofGenes · 2026Article
- Machine Learning-Based Risk Assessment of Myasthenia Gravis Onset in Thymoma Patients and Analysis of Their Correlations and Causal Relationships.Journal of imaging informatics in medicine · 2026Article
- Brief Report: Androgen Receptor Expression Is Associated With Male Predominance in Thymic Neuroendocrine Neoplasms.JTO clinical and research reports · 2026Article
- Low GBX2 expression is associated with histological type B thymoma: a multi-omics analysis.Discover oncology · 2026Article
- Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.Cancer research · 2026Article
- Somatic and germline genomic variation in thymic carcinomas.ESMO open · 2026Article
- Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes.Discover oncology · 2026Article
- Genome-wide analysis of somatic noncoding mutation patterns and mitochondrial heteroplasmic shift in type B1 and B2 thymomas.The Journal of pathology · 2026Article
- Subtype-Dependent Expression Patterns of Core Hippo Pathway Components in Thymic Epithelial Tumors (TETs): An RT-qPCR Study.Biomedicines · 2026Article
180 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 5 countries.
Milan RadovichIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
Curtis R PickeringMD Anderson Cancer Center, Houston, TX 77030, USA.
Ina FelauNational Cancer Institute, Bethesda, MD 20892, USA.
Gavin HaBroad Institute, Cambridge, MA 02142, USA.
Hailei ZhangBroad Institute, Cambridge, MA 02142, USA.
Heejoon JoDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Katherine A HoadleyDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pavana AnurOregon Health & Science University, Portland, OR 97239, USA.
Jiexin ZhangMD Anderson Cancer Center, Houston, TX 77030, USA.
Mike McLellanMcDonnell Genome Institute at Washington University, St. Louis, MO 63108, USA.
Reanne BowlbyCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Thomas MatthewUniversity of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Ludmila DanilovaJohn Hopkins University, Baltimore, MD 21231, USA.
Apurva M HegdeMD Anderson Cancer Center, Houston, TX 77030, USA.
Jaegil KimBroad Institute, Cambridge, MA 02142, USA.
Mark D M LeisersonDepartment of Computer Science & Center for Computational Molecular Biology, Brown University, Providence, RI 02912, USA.
Geetika SethiInstitute for Systems Biology, Seattle, WA 98109, USA.
Charles LuMcDonnell Genome Institute at Washington University, St. Louis, MO 63108, USA.
Michael RyanMD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaoping SuMD Anderson Cancer Center, Houston, TX 77030, USA.
Andrew D CherniackBroad Institute, Cambridge, MA 02142, USA.
Gordon RobertsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
Rehan AkbaniMD Anderson Cancer Center, Houston, TX 77030, USA.
Paul SpellmanOregon Health & Science University, Portland, OR 97239, USA.
John N WeinsteinMD Anderson Cancer Center, Houston, TX 77030, USA.
D Neil HayesDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ben RaphaelDepartment of Computer Science & Center for Computational Molecular Biology, Brown University, Providence, RI 02912, USA.
Tara LichtenbergNationwide Children's Hospital, Columbus, OH 43205, USA.
Kristen LeraasNationwide Children's Hospital, Columbus, OH 43205, USA.
Jean Claude ZenklusenNational Cancer Institute, Bethesda, MD 20892, USA.
Cancer Genome Atlas Network
Junya FujimotoMD Anderson Cancer Center, Houston, TX 77030, USA.
Cristovam Scapulatempo-NetoPathology Department and Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
Andre L MoreiraNew York University, New York City, NY 10012, USA.
David HwangUniversity Health Network, Toronto, ON M5G 2C4, Canada.
James HuangMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mirella MarinoDepartment of Pathology, Regina Elena National Cancer Institute, Rome 00144, Italy.
Robert KorstValley Health System, Ridgewood, NJ 07450, USA.
Giuseppe GiacconeGeorgetown University, Washington, DC 20057, USA.
Yesim Gokmen-PolarIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
Sunil BadveIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
Arun RajanNational Cancer Institute, Bethesda, MD 20892, USA.
Philipp StröbelUniversity Medical Center, Göttingen 37075, Germany.
Nicolas GirardInstitute of Oncology, Cardiobiotec, Hospices Civils de Lyon, Lyon 69002, France.
Ming S TsaoPrincess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Alexander MarxUniversity Medical Centre Mannheim, University of Heidelberg, Mannheim 68167, Germany.
Anne S TsaoMD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: astsao@mdanderson.org.
Patrick J LoehrerIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA. Electronic address: ploehrer@iu.edu.
The University of Texas MD Anderson Cancer Center · USBroad Institute · USIndiana University Health · USNational Cancer Institute · USUniversity of North Carolina at Chapel Hill · USBC Cancer Agency · CABrown University · USJames S. McDonnell Foundation · USNationwide Children's Hospital · USOregon Health & Science University · USGeorgetown University · USHeidelberg University · DEHospices Civils de Lyon · FRHospital de Câncer de Barretos · BRInstitute for Systems Biology · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USNew York University · USPrincess Margaret Cancer Centre · CAUniversitätsmedizin Göttingen · DE
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MLarge Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7MX-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MGene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8MGenome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0MThe Cancer Genome Atlas Data Analysis CenterU24CA143845 · NCI · BROAD INSTITUTE, INC. · PI CHIN, LYNDA, GETZ, GAD A · 2009 to 2016
$16.0MHarvard Genome Characterization CenterU24CA144025 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHERLAPATI, RAJU S. · 2009 to 2016
$14.0MThe USC-JHU Cancer Epigenome Characterization CenterU24CA143882 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BAYLIN, STEPHEN B., WEISENBERGER, DANIEL JOSEPH · 2009 to 2016
$13.3MMSKCC Center for Translational Cancer Genomic AnalysisU24CA143840 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC, SANDER, CHRIS · 2009 to 2016
$11.5MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS U24 CA143799NCI NIH HHS U24 CA143835NCI NIH HHS U24 CA143840NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143866NCI NIH HHS U24 CA143867NCI NIH HHS U24 CA143882NCI NIH HHS U24 CA143883NCI NIH HHS U24 CA144025NCI NIH HHS U24 CA210949NCI NIH HHS U24 CA210950NCI NIH HHS U24 CA210957NCI NIH HHS U24 CA210990NCI NIH HHS U24 CA210999NCI NIH HHS U24 CA211000NHGRI NIH HHS R01 HG007069NHGRI NIH HHS U54 HG003067NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG003273NIEHS NIH HHS P30 ES010126
Abstract
Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among TETs, thymoma is the most predominant, characterized by a unique association with autoimmune diseases, followed by thymic carcinoma, which is less common but more clinically aggressive. Using multi-platform omics analyses on 117 TETs, we define four subtypes of these tumors defined by genomic hallmarks and an association with survival and World Health Organization histological subtype. We further demonstrate a marked prevalence of a thymoma-specific mutated oncogene, GTF2I, and explore its biological effects on multi-platform analysis. We further observe enrichment of mutations in HRAS, NRAS, and TP53. Last, we identify a molecular link between thymoma and the autoimmune disease myasthenia gravis, characterized by tumoral overexpression of muscle autoantigens, and increased aneuploidy.
Indexed as
AdolescentAdultAgedAged, 80 and overFemaleGenomicsHumansMaleMiddle AgedMutationNeoplasms, Glandular and EpithelialThymomaThymus NeoplasmsTranscription Factors, TFIIYoung AdultGTF2I protein, humanTranscription Factors, TFIIautoimmunitygenomicsmyasthenia gravisproteomicsTCGAthymic carcinomathymic epithelial tumorsthymomatranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05832827ClinicalTrials.gov
NCT07343453ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.